Table 1.
Characteristics of patients with lung cancer.
| Characteristics | Patients (n = 97) |
|---|---|
| Age, mean ± SD, years | 67.5 ± 10.2 |
| Males, n (%) | 55 (56.7%) |
| Height, mean ± SD, cm | 168.1 ± 8.7 |
| Weight, mean ± SD, kg | 73.8 ± 15.6 |
| BMI, mean ± SD, kg·m−2 | 26.1 ± 4.9 |
| BMI, categories, n (%) | |
| Underweight | 4 (4.1%) |
| Normal weight | 34 (35.1%) |
| Overweight | 43 (44.3%) |
| Obese | 16 (16.5%) |
| Current smoker, n (%) a | 74 (83.1%) |
| Tumour type, n (%) | |
| Adenocarcinoma | 61 (62.9%) |
| Adeno-squamous | 1 (1.0%) |
| Large cell carcinoma | 2 (2.1%) |
| Poorly differentiated | 3 (3.1%) |
| Pleomorphic | 1 (1.0%) |
| Squamous cell carcinoma | 29 (29.9%) |
| Cancer stage, n (%) a | |
| III | 15 (15.6%) |
| IV | 81 (84.4%) |
| Metastasis location, n (%) a | |
| No metastasis | 14 (40%) |
| Adrenal | 1 (2.9%) |
| Bone | 6 (17.1%) |
| Brain | 1 (2.9%) |
| Liver | 2 (5.7%) |
| Lymph node | 3 (8.6%) |
| ≥2 sites | 8 (22.9%) |
| Treatment line, n (%) | |
| First line treatment | 24 (24.7%) |
| Second line treatment | 73 (75.3%) |
| Treatment, n (%) | |
| Atezolumab | 16 (16.5%) |
| Nivolumab | 57 (58.8%) |
| Pembrolizumab | 24 (24.7%) |
| ECOG, n (%) a | |
| 0 | 49 (51.0%) |
| 1 | 34 (35.5%) |
| 2 | 12 (12.5%) |
| 3 | 1 (1.0%) |
| Neutrophils, mean ± SD | 6.6 ± 4.4 |
| Lymphocytes, mean ± SD | 1.5 ± 0.8 |
| Haemoglobin, mean ± SD | 125.2 ± 20.4 |
| Platelets, mean ± SD | 306.1 ± 122.0 |
| Neutrophils-to-lymphocytes ratio, mean ± SD | 6.9 ± 11.6 |
| PD-L1 levels, median (IQR), % | 60.0 (1.0 to 80.0) |
BMI, Body mass index; ECOG, Eastern Cooperative Oncology Group performance status; IQR, interquartile range; SD, standard deviation; a, missing data: current smoker, n = 8; cancer stage, n = 1; TNM, n = 16; metastasis location, n = 62; ECOG, n = 1.